Related Experiment Video
Updated: Dec 11, 2025
07:24
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
6.7K
The SLAMF3 rs509749 polymorphism correlates with malignant potential in multiple myeloma
Mariko Ishibashi1, Mika Sunakawa-Kii2, Yuta Kaito2
1Department of Microbiology and Immunology, Nippon Medical School, Tokyo, Japan.
Experimental Hematology
|August 21, 2020
Summary
A specific gene variant in signaling lymphocytic activation molecule family 3 (SLAMF3) is linked to poorer outcomes in multiple myeloma (MM). This SLAMF3 SNP (rs509749) G allele promotes cancer cell growth and resistance to treatment, suggesting a role in MM progression.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- Signaling lymphocytic activation molecule family 3 (SLAMF3) is highly expressed in multiple myeloma (MM) plasma cells.
- SLAMF3 signaling, involving SHP2 and GRB2, contributes to MM malignancy and ERK pathway activation.
- Single-nucleotide polymorphisms (SNPs) in cancer-related genes can influence disease progression and patient outcomes.
Purpose of the Study:
- To investigate the association of the SLAMF3 gene single-nucleotide polymorphism (SNP) rs509749 (1804A>G, M602V) with multiple myeloma (MM).
- To evaluate the impact of the SLAMF3 rs509749 SNP genotypes on MM patient survival and disease progression.
- To determine the functional consequences of the SLAMF3 G allele (V602) on MM cell behavior and signaling pathways.
Main Methods:
- Genotyping analysis of the SLAMF3 rs509749 SNP in MM patients and healthy controls from the Japanese population.
- Correlation analysis between SLAMF3 genotypes and overall survival in MM patients.
- In vitro and in vivo studies using MM cell lines (KMS-34) with different SLAMF3 alleles (M602 vs. V602) and NOG mouse models.
Main Results:
- The G allele of SLAMF3 rs509749 was frequent in MM patients, with GG genotype associated with significantly shorter overall survival compared to GA/AA genotypes.
- SLAMF3-overexpressing cells with the G allele (V602) exhibited enhanced proliferation, increased resistance to anti-MM agents, and promoted tumor growth in vivo.
- The V602 variant showed increased binding to SHP2 and GRB2, leading to elevated SHP2 and ERK phosphorylation, and upregulated expression of cell cycle and anti-apoptotic genes.
Conclusions:
- The G allele of the SLAMF3 SNP rs509749 (V602) is associated with increased malignant potential and poorer survival in multiple myeloma patients.
- This genetic variant enhances MM cell proliferation, drug resistance, and tumor growth through altered SLAMF3-mediated signaling.
- SLAMF3 rs509749 SNP may serve as a potential biomarker for predicting MM disease progression and patient outcomes.
